David Hollenback

机构：Phenex Pharmaceuticals (Germany), Gilead Sciences (United States) · ORCID：0000-0002-4149-7848

发表论文 39 篇 · 总被引 603 次 · h-index 11

代表论文

• Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation (2020 · Journal of Hepatology · 被引 230)
• Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia (2014 · Molecular Cancer Therapeutics · 被引 35)
• Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-/- mouse model of sclerosing cholangitis (2023 · JHEP Reports · 被引 20)
• Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis (2022 · Hepatology Communications · 被引 15)
• Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease (2024 · Journal of Pharmacology and Experimental Therapeutics · 被引 6)
• Combination of an ASK1 inhibitor and FXR agonist increases efficacy in a mouse model of non-alcoholic steatohepatitis (2017 · Journal of Hepatology · 被引 3)